Bolden Therapeutics: Funding, Investors & Team (Oct 2026)
Bolden Therapeutics is a biotech firm that focuses on creating innovative treatments for diseases affecting the central nervous system.
Bolden Therapeutics has raised $410k across 2 funding rounds on record, the most recent an undisclosed round announced in Jan 2024.
Bolden Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2024.
Bolden Therapeutics Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Bolden Therapeutics raised $410k in a Grant announced in Sep 2022.
1.3 years later, an undisclosed round was announced in Jan 2024 with no disclosed amount.
Bolden Therapeutics Founders and Leadership Team
Contact details for the Bolden Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Bolden Therapeutics Funding Compared to Other Biotechnology Startups
Funded Startups Like Bolden Therapeutics in Biotechnology and Providence
Companies Similar to Bolden Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Bolden Therapeutics Funding FAQs
What does Bolden Therapeutics do?
Bolden Therapeutics is a biotech firm that focuses on creating innovative treatments for diseases affecting the central nervous system.
How much funding has Bolden Therapeutics raised?
Bolden Therapeutics has raised $410k across 2 rounds on record.
When did Bolden Therapeutics last raise funding?
Bolden Therapeutics' most recent funding round on record was announced in Jan 2024. The amount was not disclosed.
Who founded Bolden Therapeutics?
FundedIQ lists Johnny Page (Founder) at Bolden Therapeutics.
Where is Bolden Therapeutics headquartered?
Bolden Therapeutics is based in Providence, Rhode Island, United States.
How many employees does Bolden Therapeutics have?
Bolden Therapeutics is in the 1-10 employee band.
About FundedIQ's Bolden Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bolden Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.